下半场怎么看可以抄底吗

Summary of Conference Call on the Pharmaceutical Industry Industry Overview - The pharmaceutical industry is expected to experience a certain degree of reversal in the second half of 2024, primarily due to increased policy support, especially for the innovative drug sector, which provides strong backing for the industry's development [1][2][3] Key Policies and Support - A series of significant policies targeting the innovative drug sector have been introduced this year, including a scoring mechanism for new chemical drugs post-launch, comprehensive support documents for innovative drug development, and local government support policies [1][3] - Specific local government initiatives include: - Guangdong providing substantial financial support for innovative drug projects, with individual project funding potentially exceeding 100 million yuan [4] - Beijing establishing an exclusion list for new drugs and materials to encourage their use in hospitals, alongside expedited clinical approval processes [4] - Zhuhai offering both financial and clinical support for innovative drugs [4] Industry Recognition and Achievements - The recent oncology academic conference and the European Society for Medical Oncology (ESMO) conference were significant for the innovative drug industry, with Chinese companies submitting 50 reports, doubling last year's submissions, and five reports being selected for the highest level of abstracts [1][4] - The domestic dual-antibody product AK112 successfully challenged Merck's K drug, marking a milestone in global pharmaceutical history and demonstrating China's capability to develop superior treatment options [5][6] Global Positioning - China's innovative drug industry has become a crucial driver of global innovation in pharmaceuticals, particularly in cancer drug development, with notable advancements in combination therapy [7] Investment Insights - Investors are encouraged to focus on the medium to long-term trends and capitalize on policy dividends that present investment opportunities [2][12] - The current market environment, characterized by low valuations and strong fundamentals, suggests a relatively safe position for increasing risk appetite [12] Challenges and Considerations - Factors influencing the pharmaceutical industry include anti-corruption actions and geopolitical conflicts, which may impact specific stocks but pose limited overall risk [13] - The aging population and increasing pressure on medical insurance payments necessitate innovative solutions as the only viable path forward [13] Recommendations for Investors - Ordinary investors are advised to maintain a long-term perspective in the healthcare sector, focusing on continuous learning and diversification of income sources to navigate market volatility [14]